ICICI Securities has issued a 'Buy' rating for Nephrocare Health Services with a target price of Rs 825, driven by strong international expansion. While the brokerage highlights growth in the Philippines, Saudi Arabia, and Kazakhstan, the company is also closing a 'Dial a Dialysis' unit in Kolkata due to regulatory constraints.
ICICI Securities has initiated coverage on Nephrocare Health Services with a 'Buy' rating, setting a target price of Rs 825 per share. The brokerage’s outlook is based on a valuation of 33 times the projected earnings per share for the 2028 fiscal year. The firm's optimistic view rests primarily on Nephrocare’s aggressive international expansion strategy, which has become a significant driver of revenue and profitability.
Nephrocare has been scaling its operations beyond India, with a strong focus on markets like the Philippines, Saudi Arabia, and Kazakhstan. The company’s business model in these regions benefits from higher realization rates per dialysis session compared to its domestic Indian operations. Data indicates that international centers generate significantly higher revenue per session, providing a wider margin buffer for the company. The strategy involves entering one new international territory every 12 to 18 months to sustain this growth.
While international performance remains a central pillar of the brokerage's positive outlook, investors should also be aware of operational and regulatory risks. The company recently announced the closure of its 'Dial a Dialysis' (DAD) unit in Kolkata, effective September 15, 2026. This decision follows regulatory and licensing constraints in that specific region. This event highlights the complexities of the healthcare sector, where operations are frequently subject to local laws and licensing requirements that can impact service continuity.
Beyond regulatory hurdles, the company faces structural risks inherent in the dialysis business. Nephrocare has a heavy reliance on captive clinic contracts and Public-Private Partnership (PPP) tenders with government bodies. Any policy changes regarding these tenders or delays in contract renewals could affect revenue stability. Additionally, the business model is service-intensive, making it sensitive to attrition rates among skilled medical professionals, particularly nephrologists and trained nursing staff. Managing these human resource costs while maintaining service quality remains a critical operational challenge.
Looking ahead, market participants will likely monitor the execution of the company's international roadmap. The success of its expansion into the Middle East and Central Asia will be pivotal, as the company seeks to scale these new facilities while navigating the regulatory environment in each country. Furthermore, investors may track whether the company can mitigate the impact of domestic regulatory closures and maintain its profit margins amidst rising operational costs and the need for skilled talent.